FDA Grants Priority Review for J&J's Rybrevant Faspro in Head and Neck Cancer

The FDA has granted Priority Review to Johnson & Johnson's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after prior treatments. This designation accelerates the review process, indicating the FDA sees potential for significant improvements in treating this serious condition.